Biopharmaceutical firm Urovant Sciences announced that it has licensed global rights for the development and commercialisation of hMaxi-K-K, a novel investigational gene therapy for the treatment of overactive bladder (OAB). The company will study the potential of hMaxi-K-K as a treatment for patients with OAB symptoms for whom oral pharmacologic therapy has not been successful. It expects to initiate the Phase 2 hMaxi-K-K study next year.
Biopharmaceutical firm Urovant Sciences announced that it has licensed global rights for the development and commercialisation of hMaxi-K, a novel investigational gene therapy for the treatment of overactive bladder (OAB). The company will study the potential of hMaxi-K as a treatment for patients with OAB symptoms for whom oral pharmacologic therapy has not been successful. It expects to initiate the Phase 2 hMaxi-K study next year.